Somewhat Critical Media Coverage Somewhat Likely to Affect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Share Price

Media headlines about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have been trending somewhat negative recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals Corporation earned a news impact score of -0.06 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 63 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

ADMP has been the topic of several recent research reports. Maxim Group restated a “buy” rating and set a $10.00 target price on shares of Adamis Pharmaceuticals Corporation in a report on Monday, June 12th. ValuEngine upgraded Adamis Pharmaceuticals Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th.

Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) remained flat at $4.60 on Tuesday. The company had a trading volume of 207,353 shares. The stock’s 50 day moving average price is $5.02 and its 200 day moving average price is $4.16. Adamis Pharmaceuticals Corporation has a 1-year low of $2.40 and a 1-year high of $6.45. The stock’s market cap is $126.79 million.

COPYRIGHT VIOLATION NOTICE: “Somewhat Critical Media Coverage Somewhat Likely to Affect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Share Price” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/somewhat-negative-media-coverage-somewhat-likely-to-impact-adamis-pharmaceuticals-corporation-nasdaqadmp-stock-price-updated-updated-updated/1194346.html.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Insider Buying and Selling by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.